Clinical trials: Small Cell and Non-small Cell Lung Cancer
Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Pilot Phase II Study The primary objective for this study is: To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before…
- Conditions
- Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
- Trial name
- K5-101 (NCT00988936)
- Testing
- [F-18]RGD-K5
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Siemens Molecular Imaging
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Ewings Sarcoma, Non Small Cell Lung Cancer
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting…
- Conditions
- Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
- Trial name
- NCT01061840
- Testing
- Vigil™
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Gradalis, Inc.
Cancer
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Heat shock protein 90 (Hsp90) is a chemical in the body that is involve in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
- Trial name
- NCT01892046
- Testing
- SNX-5422
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Esanex Inc.
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
This is a multicenter, two part (Part A and Part B) clinical study of CMP-001 administered intratumorally (IT) and subcutaneously (SC) in combination with atezolizumab with or without radiation therapy in participants with NSCLC.
- Trial name
- NCT03438318
- Testing
- CMP-001, Atezolizumab, Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Regeneron Pharmaceuticals
Thrombosis, Venous
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
- Trial name
- NCT00312013
- Testing
- Nadroparin
- Where
- 95 sites in Belgium, Canada and 9 more
- Volunteers
- 503 people
- Sponsor
- GlaxoSmithKline
Colorectal, Pancreatic
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V…
- Conditions
- Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT06767046
- Testing
- KRAS-specific Autologous TCR-T cell injection
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Non-Small Cell Lung Cancer
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with…
- Trial name
- NCT05240131
- Testing
- GB1211, Atezolizumab
- Where
- 5 sites in France, Poland and 1 more
- Volunteers
- 88 people
- Sponsor
- Galecto Biotech AB
Malignant Pleural Effusions, NSCLC Stage IV
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
- Trial name
- NCT05543330
- Testing
- M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Healthy Volunteer
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers.
- Trial name
- NCT02224053
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing
- Where
- 2 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Small Cell Lung Carcinoma
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide guidance to the Physician for the treatment and monitoring of eligible patients diagnosed with BRAF V600E/K activating mutation-positive…
- Trial name
- NCT04507919
- Testing
- Dabrafenib, Trametininb
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.
- Trial name
- NCT00424775
- Testing
- MK0683, vorinostat
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of…
- Trial name
- NCT00106626
- Testing
- vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl.
- Trial name
- NAUTIC (NCT06494540)
- Where
- 30 sites in Germany
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab…
- Trial name
- PACIFIC-9 (NCT05221840)
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 202 sites in United States, Australia and 18 more
- Volunteers
- 1,051 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Cancer of the Head and Neck
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
The purpose of this study is to provide ZD1839 for those patients with locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV) or recurrent and/or metastatic squamous cell head and neck cancer…
- Trial name
- NCT00684385
- Testing
- ZD1839
- Where
- 34 sites in Germany, Hungary and 2 more
- Sponsor
- AstraZeneca
Non-small-cell Lung Cancer
A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer
This study will evaluate the efficacy and safety of QL1706 when given in combination with bevacizumab, paclitaxel or pemetrexed, and carboplatin in patients with Stage IIIB/C and Stage IV Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT05329025
- Testing
- QL1706
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
CK-101 is a novel, potent, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Adenocarcinoma
- Trial name
- NCT02926768
- Testing
- CK-101
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 136 people
- Sponsor
- Checkpoint Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.